Last reviewed · How we verify
Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer (IREKI)
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.
Details
| Lead sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | 2021-12-06 |
| Completion | 2026-03 |
Conditions
- Kidney Neoplasm
Interventions
- blood sampling for ITK dosage
Primary outcomes
- Residual concentration at equilibrium of ITK in the blood — at 1 month (+/1 week)
Assessment in patients treated for metastatic kidney cancer without or with moderate or severe renal impairment if the plasma concentration (residual concentration at equilibrium) of ITK is higher than the target concentration (specific to the ITK molecule : pazopanib : 20 000 ng/mL and cabozantinib : 1000 ng/mL )
Countries
France